EA202092265A1 - Антитела против cd137 для комбинации с антителами против pd-l1 - Google Patents
Антитела против cd137 для комбинации с антителами против pd-l1Info
- Publication number
- EA202092265A1 EA202092265A1 EA202092265A EA202092265A EA202092265A1 EA 202092265 A1 EA202092265 A1 EA 202092265A1 EA 202092265 A EA202092265 A EA 202092265A EA 202092265 A EA202092265 A EA 202092265A EA 202092265 A1 EA202092265 A1 EA 202092265A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies against
- combination
- antibodies
- human
- monotherapy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Данное изобретение относится к антителам, которые связываются с CD137 человека, проявляют агонистическую активность и могут быть полезны для лечения солидных и гематологических опухолей в виде монотерапии и в комбинации с антителами против PD-L1 человека, химиотерапией и ионизирующим излучением.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862647016P | 2018-03-23 | 2018-03-23 | |
PCT/US2019/022391 WO2019182878A1 (en) | 2018-03-23 | 2019-03-15 | Anti-cd137 antibodies for combination with anti-pd-l1 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202092265A1 true EA202092265A1 (ru) | 2020-12-24 |
Family
ID=65952174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202092265A EA202092265A1 (ru) | 2018-03-23 | 2019-03-15 | Антитела против cd137 для комбинации с антителами против pd-l1 |
Country Status (13)
Country | Link |
---|---|
US (1) | US12037406B2 (ru) |
EP (1) | EP3768711B1 (ru) |
JP (1) | JP7059388B2 (ru) |
KR (1) | KR102432046B1 (ru) |
CN (1) | CN112020517A (ru) |
AU (1) | AU2019239194B2 (ru) |
CA (1) | CA3094763C (ru) |
EA (1) | EA202092265A1 (ru) |
ES (1) | ES2946343T3 (ru) |
IL (1) | IL277510A (ru) |
MA (1) | MA52075A (ru) |
MX (1) | MX2020009863A (ru) |
WO (1) | WO2019182878A1 (ru) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3585431A4 (en) | 2017-02-24 | 2020-12-16 | MacroGenics, Inc. | BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING TO CD137 AND TUMOR ANTIGENS, AND THEIR USES |
MA52076A (fr) * | 2018-03-23 | 2021-01-27 | Lilly Co Eli | Anticorps anti-cd137 pour une combinaison avec des anticorps anti-pd-1 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6362325B1 (en) | 1988-11-07 | 2002-03-26 | Advanced Research And Technology Institute, Inc. | Murine 4-1BB gene |
US6303121B1 (en) | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
US7211259B1 (en) | 1993-05-07 | 2007-05-01 | Immunex Corporation | 4-1BB polypeptides and DNA encoding 4-1BB polypeptides |
BR9712278A (pt) | 1996-10-11 | 1999-08-31 | Bristol Myers Squibb Co | Processos e composições para imunomodulação |
US7651686B2 (en) | 2001-10-09 | 2010-01-26 | Mayo Foundation For Medical Education And Research | Enhancement of immune responses by 4-1bb-binding agents |
US7288638B2 (en) * | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
WO2010042433A1 (en) | 2008-10-06 | 2010-04-15 | Bristol-Myers Squibb Company | Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases |
CN105481983B (zh) | 2010-09-09 | 2021-09-03 | 辉瑞公司 | 4-1bb结合分子 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
EP3102604B1 (en) | 2014-02-04 | 2020-01-15 | Pfizer Inc | Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer |
US20170247455A1 (en) | 2014-08-22 | 2017-08-31 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
CN112546238A (zh) | 2014-09-01 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
MX2017010793A (es) | 2015-02-22 | 2018-07-06 | Sorrento Therapeutics Inc | Terapeuticos de anticuerpo que ligan cd137. |
ES2936317T3 (es) * | 2015-05-29 | 2023-03-16 | Bristol Myers Squibb Co | Anticuerpos contra OX40 y usos de los mismos |
CN107771184B (zh) * | 2015-06-29 | 2022-11-01 | 百时美施贵宝公司 | 针对cd40的抗体 |
WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
GB201619648D0 (en) | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel antibodies and uses thereof |
US11512134B2 (en) * | 2017-08-01 | 2022-11-29 | Eli Lilly And Company | Anti-CD137 antibodies |
SG11202000747VA (en) * | 2017-08-01 | 2020-02-27 | Lilly Co Eli | Anti-cd137 antibodies |
MA52076A (fr) * | 2018-03-23 | 2021-01-27 | Lilly Co Eli | Anticorps anti-cd137 pour une combinaison avec des anticorps anti-pd-1 |
JP7090204B2 (ja) | 2018-07-19 | 2022-06-23 | イーライ リリー アンド カンパニー | 免疫チェックポイントを標的とする二重特異性抗体 |
AU2019369498A1 (en) | 2018-10-31 | 2021-05-20 | Delinia, Inc. | Multivalent regulatory T cell modulators |
-
2019
- 2019-03-15 KR KR1020207030371A patent/KR102432046B1/ko active IP Right Grant
- 2019-03-15 ES ES19714024T patent/ES2946343T3/es active Active
- 2019-03-15 AU AU2019239194A patent/AU2019239194B2/en active Active
- 2019-03-15 MX MX2020009863A patent/MX2020009863A/es unknown
- 2019-03-15 US US17/040,380 patent/US12037406B2/en active Active
- 2019-03-15 CA CA3094763A patent/CA3094763C/en active Active
- 2019-03-15 MA MA052075A patent/MA52075A/fr unknown
- 2019-03-15 EP EP19714024.7A patent/EP3768711B1/en active Active
- 2019-03-15 WO PCT/US2019/022391 patent/WO2019182878A1/en active Application Filing
- 2019-03-15 CN CN201980021462.2A patent/CN112020517A/zh active Pending
- 2019-03-15 JP JP2020549572A patent/JP7059388B2/ja active Active
- 2019-03-15 EA EA202092265A patent/EA202092265A1/ru unknown
-
2020
- 2020-09-22 IL IL277510A patent/IL277510A/en unknown
Also Published As
Publication number | Publication date |
---|---|
ES2946343T3 (es) | 2023-07-17 |
WO2019182878A1 (en) | 2019-09-26 |
JP2021516249A (ja) | 2021-07-01 |
MX2020009863A (es) | 2021-01-08 |
AU2019239194A1 (en) | 2020-10-15 |
US12037406B2 (en) | 2024-07-16 |
EP3768711B1 (en) | 2023-05-03 |
MA52075A (fr) | 2021-01-27 |
IL277510A (en) | 2020-11-30 |
CN112020517A (zh) | 2020-12-01 |
EP3768711A1 (en) | 2021-01-27 |
AU2019239194B2 (en) | 2023-09-14 |
JP7059388B2 (ja) | 2022-04-25 |
CA3094763A1 (en) | 2019-09-26 |
KR20200134289A (ko) | 2020-12-01 |
CA3094763C (en) | 2024-01-02 |
US20210054088A1 (en) | 2021-02-25 |
KR102432046B1 (ko) | 2022-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202090204A1 (ru) | Анти-cd137 антитела | |
EA201890278A1 (ru) | Антитела к pd-l1 | |
EA201992757A1 (ru) | Биспецифические антитела-ингибиторы контрольной точки | |
PH12019501253A1 (en) | Anti-tim-3 antibodies for combination with anti-pd-1 antibodies | |
PH12021550337A1 (en) | Anti-gdf15 antibodies, compositions and methods of use | |
MY195110A (en) | Antibodies to PD-1 and uses Thereof | |
EA202091540A1 (ru) | Антитела к lilrb2 | |
EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
JOP20190013A1 (ar) | أجسام مضادة لـ (تي آي ام -3) | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
EA201890158A1 (ru) | Антитела против ntb-a и связанные композиции и способы | |
EA201900561A1 (ru) | Конъюгаты циклодекстрин-белок-лекарственное средство | |
EA202190609A1 (ru) | Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g | |
EA202192796A1 (ru) | Tigit и pd-1/tigit-связывающие молекулы | |
EA202092420A1 (ru) | Антитело против pd-l1 и его применение | |
EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
EA202092262A1 (ru) | Антитела против cd137 для комбинации с антителами против pd-1 | |
EA202092085A1 (ru) | ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ | |
EA201990978A1 (ru) | Антитела против pd-1 | |
EA201891528A1 (ru) | Композиции и способы обнаружения и лечения рака желудка | |
EA201992145A1 (ru) | Анти-pd-l1-анти-tim-3 биспецифические антитела | |
EA202092265A1 (ru) | Антитела против cd137 для комбинации с антителами против pd-l1 | |
EA201891529A1 (ru) | Композиции и способы обнаружения и лечения рака яичников | |
EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
EA201990258A1 (ru) | Антитела к tim-3 |